Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine. Issue 7 (11th February 2020)

• Record Type: Journal Article
• Authors: Stinson, Jordan A.; Palmer, Carter R.; Miller, David P.; Li, Adrian B.; Lightner, Kandice; Jost, Heather; Weldon, William C.; Oberste, M. Steven; Kluge, Jonathan A.; Kosuda, Kathryn M.
• Is Part Of: Vaccine. Volume 38:Issue 7(2020)
• Page Start: 1652
• Page End: 1660
• Publication Date: 2020-02-11
• Subjects: Silk -- Fibroin -- Stabilization -- Vaccine -- Poliovirus; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.12.062
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Developed a polio vaccine format for improved product stability. Enabled by silk fibroin biomaterial with short process time and high recovery. Minimal antigen loss after nearly three years of storage at room temperature. 45 °C stressed vaccine maintained efficacy in rats: IPV-1 and IPV-2 seroconversion. Format is compatible with novel delivery systems such as microneedles. Abstract: Current inactivated polio vaccine (IPV) products are sensitive to both freezing and elevated temperatures and therefore must be shipped and stored between 2 °C and 8 °C, a requirement that imposes financial and logistical challenges for global distribution. As such, there is a critical need for a robust, thermally stable IPV to support global polio eradication and post-eradication immunization needs. Here, we present the development of air-dried thin films for temperature stabilization of IPV using the biomaterial silk fibroin. Thin-film product compositions were optimized for physical properties as well as poliovirus D-antigen recovery and were tested under accelerated and real-time stability storage conditions. Silk fibroin IPV films maintained 70% D-antigen potency after storage for nearly three years at room temperature, and greater than 50% potency for IPV-2 and IPV-3 serotypes at 45 °C for one year. The immunogenicity of silk fibroin IPV films after 2-week storage at 45 °C was assessed in Wistar rats and the stressed films generated equivalent neutralizing antibody responses to commercial vaccine for IPV-1 and IPV-2. However, the absence of IPV-3 responses warrants further investigation into the specificity of ELISA for intact IPV-3 D-antigen. By demonstrating immunogenicity post-storage, we offer the air-dried silk film format as a means to increase IPV vaccine access through innovative delivery systems such as microneedles.